INSIGHTS ON CLINICAL TRIAL DESIGN

• Ways To Avoid Rescue Trials From The Start

  What pushes a study into rescue mode? Explore the common causes of trial delays and how to address them before they impact timelines and outcomes.

• Critical Inputs For Configuring An RTSM

  Uncover why clearly defined visit schedules and dispensing events are essential in RTSM design — and how resolving protocol ambiguity early prevents downstream complexity across systems and sites.

• Health Economics And Outcomes Research (HEOR) Explained

  Learn about this accessible way to understand what HEOR is, how it’s used, and its impact on people and healthcare systems.

• What Everest Group's RTSM Recognition Means For The Industry

  RTSM is transforming from a basic operational tool into a strategic driver of trial efficiency. Learn why industry recognition signals a new era of innovation and competitive advantage.

• 5 Proven Ways To Expand Clinical Trial Site Capacity

  9/18/2025

  How can you turn capacity limits into enrollment momentum and ensure timelines stay on track while also expanding access to diverse patient populations?

• Can Your Trial Payment Approach Stand Up To Regulatory Scrutiny?

  6/15/2026

  Fragmented trial payment systems create compliance, ethical, and operational risks. Aligning payments with regulations and ethics improves transparency, reduces burden, and supports audits and participation.

• Psychedelic Drug Trials: Are Your Sites Ready?

  8/24/2026

  Psychedelic trials require unique operational approaches. Learn how to address patient safety, blinding, specialized assessments, and therapeutic setting considerations.

• Operationalizing Adaptive Design For FDA's One-Trial Era

  10/20/2026

  The FDA now accepts one pivotal trial as the default path to approval. Learn how adaptive designs can help you build a single study strong enough to stand on its own.

• Completed Clinical Trials Continued To Climb In 2024

  6/19/2025

  Data collected in this report reflects a shift toward sustained growth, reflecting rapid advancement in therapeutic areas such as oncology, autoimmune/inflammation, and central nervous system studies.